Interpace Biosciences (OTCMKTS:IDXG) Issues Earnings Results

Interpace Biosciences (OTCMKTS:IDXG – Get Free Report) released its quarterly earnings results on Monday. The business services provider reported ($0.26) EPS for the quarter, Zacks reports. Interpace Biosciences had a return on equity of 145.40% and a net margin of 67.64%. The business had revenue of $10.37 million for the quarter.

Interpace Biosciences Price Performance

IDXG stock traded down $0.52 during trading hours on Wednesday, reaching $5.48. The stock had a trading volume of 1,600 shares, compared to its average volume of 1,755. The stock has a 50-day simple moving average of $6.40 and a 200 day simple moving average of $8.05. The stock has a market capitalization of $30.37 million, a PE ratio of 13.70 and a beta of 0.67. Interpace Biosciences has a fifty-two week low of $4.95 and a fifty-two week high of $7.45.

Interpace Biosciences Company Profile

(Get Free Report)

Interpace Biosciences is a molecular diagnostics company that develops and provides tests to help clinicians assess cancer risk and guide treatment decisions. Its services combine molecular analysis with pathology and related diagnostic expertise. The company’s tests focus on conditions including pancreatic cysts and thyroid nodules. Its offerings have included PancraGEN for pancreatic cyst assessment, as well as ThyGeNEXT and ThyraMIR for evaluating thyroid nodules. Interpace has also offered molecular testing for gastrointestinal cancers.

Featured Articles

Earnings History for Interpace Biosciences (OTCMKTS:IDXG)

Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.